Soligenix Operating Margin 2010-2022 | SNGX
Current and historical operating margin for Soligenix (SNGX) over the last 10 years. The current operating profit margin for Soligenix as of March 31, 2022 is -1710.71%.
| Soligenix Operating Margin Historical Data |
| Date |
TTM Revenue |
TTM Operating Income |
Operating Margin |
| 2022-03-31 |
$0.00B |
$-0.02B |
inf% |
| 2021-12-31 |
$0.00B |
$-0.01B |
inf% |
| 2021-09-30 |
$0.00B |
$-0.01B |
inf% |
| 2021-06-30 |
$0.00B |
$-0.01B |
-1200.00% |
| 2021-03-31 |
$0.00B |
$-0.01B |
-600.00% |
| 2020-12-31 |
$0.00B |
$-0.02B |
-600.00% |
| 2020-09-30 |
$0.00B |
$-0.02B |
-400.00% |
| 2020-06-30 |
$0.00B |
$-0.02B |
-425.00% |
| 2020-03-31 |
$0.01B |
$-0.02B |
-320.00% |
| 2019-12-31 |
$0.01B |
$-0.01B |
-200.00% |
| 2019-09-30 |
$0.01B |
$-0.01B |
-200.00% |
| 2019-06-30 |
$0.01B |
$-0.01B |
-180.00% |
| 2019-03-31 |
$0.01B |
$-0.01B |
-180.00% |
| 2018-12-31 |
$0.01B |
$-0.01B |
-180.00% |
| 2018-09-30 |
$0.01B |
$-0.01B |
-180.00% |
| 2018-06-30 |
$0.01B |
$-0.01B |
-133.33% |
| 2018-03-31 |
$0.01B |
$-0.01B |
-160.00% |
| 2017-12-31 |
$0.01B |
$-0.01B |
-160.00% |
| 2017-09-30 |
$0.01B |
$-0.01B |
-100.00% |
| 2017-06-30 |
$0.01B |
$-0.01B |
-85.71% |
| 2017-03-31 |
$0.01B |
$-0.01B |
-55.56% |
| 2016-12-31 |
$0.01B |
$-0.01B |
-45.45% |
| 2016-09-30 |
$0.01B |
$-0.01B |
-50.00% |
| 2016-06-30 |
$0.01B |
$-0.01B |
-46.15% |
| 2016-03-31 |
$0.01B |
$-0.01B |
-63.64% |
| 2015-12-31 |
$0.01B |
$-0.01B |
-77.78% |
| 2015-09-30 |
$0.01B |
$-0.01B |
-87.50% |
| 2015-06-30 |
$0.01B |
$-0.01B |
-157.14% |
| 2015-03-31 |
$0.01B |
$-0.01B |
-157.14% |
| 2014-12-31 |
$0.01B |
$-0.01B |
-157.14% |
| 2014-09-30 |
$0.01B |
$-0.01B |
-166.67% |
| 2014-06-30 |
$0.00B |
$-0.01B |
-233.33% |
| 2014-03-31 |
$0.00B |
$-0.01B |
-266.67% |
| 2013-12-31 |
$0.00B |
$-0.01B |
-233.33% |
| 2013-09-30 |
$0.00B |
$-0.01B |
-266.67% |
| 2013-06-30 |
$0.00B |
$-0.01B |
-175.00% |
| 2013-03-31 |
$0.00B |
$-0.01B |
-125.00% |
| 2012-12-31 |
$0.00B |
$-0.01B |
-125.00% |
| 2012-09-30 |
$0.00B |
$-0.01B |
-125.00% |
| 2012-06-30 |
$0.01B |
$-0.00B |
-22.22% |
| 2012-03-31 |
$0.01B |
$-0.00B |
-37.50% |
| 2011-12-31 |
$0.01B |
$-0.00B |
-50.00% |
| 2011-09-30 |
$0.01B |
$-0.00B |
-57.14% |
| 2011-06-30 |
$0.00B |
$-0.01B |
-400.00% |
| 2011-03-31 |
$0.00B |
$-0.01B |
-400.00% |
| 2010-12-31 |
$0.00B |
$-0.01B |
-800.00% |
| 2010-09-30 |
$0.00B |
$-0.01B |
-300.00% |
| 2010-06-30 |
$0.00B |
$-0.01B |
-300.00% |
| 2010-03-31 |
$0.00B |
$-0.01B |
-300.00% |
| 2009-12-31 |
$0.00B |
$-0.01B |
-200.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.026B |
$0.001B |
|
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases where, as well as developing several biodefense vaccines and therapeutics. The Company operates in two reportable segments: BioTherapeutics and BioDefense. The BioTherapeutics business segment intends to develop orBec ? (oral beclomethasone dipropionate, or oral BDP) and other biotherapeutic products, including LPM TM Leuprolide. The BioDefense business segment intends to convert its ricin toxin vaccine and radiation injury programs from early stage development to advanced development and manufacturing. Soligenix, Inc, formerly known as DOR BioPharma, Inc, is headquartered in Princeton, New Jersey.
|
